We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 39

Medicinova and Zhejiang Medicine announce joint venture in China
  • Shook Hardy & Bacon LLP
  • China, USA
  • March 10 2011

California-based biopharmaceutical company MediciNova Inc. and Zhejiang Medicine Co., a Chinese pharmaceutical manufacturer, have announced a joint venture to develop and commercialize MediciNova’s MN-221 in China


Barbados launches biotech initiative designed to shorten R&D process
  • Shook Hardy & Bacon LLP
  • Barbados
  • December 16 2010

The Barbados government has recently launched two initiatives to attract biotech companies to the island nation


Corporate venture funding for funding surges
  • Shook Hardy & Bacon LLP
  • USA
  • August 7 2014

Silicon Valley Bank (SVB) has issued a report that explores health-care and biotech investments and exits based on 2013 data and concludes, "Large


U.S. biotech sector shows IPO gains in 2013
  • Shook Hardy & Bacon LLP
  • USA
  • June 6 2013

According to Reuters, 14 biotech companies have gone public so far in 2013, marking a possible turnaround for the sector with a rising stock market


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe


Molecular diagnostics company nets $27.7 million from common stock offering
  • Shook Hardy & Bacon LLP
  • USA
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including


Biotech IPO boom continues
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

According to Xconomy's National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen


Biotech raises $30 million to develop rare muscle disease treatments
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

San Francisco-based Audentes Therapeutics Inc. has closed a $30-million Series A financing round led by OrbiMed Advisors and including 5AM Ventures


Biotech investments rise in Q4 2012, but remain off for the year
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology


North Carolina life sciences companies attract more than $1.1 billion in investments, grants
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

After conducting its yearly survey of media reports, a North Carolina trade association has announced that life sciences companies brought in more than $1.1 billion in investments and grants to the state in the 12 months ending April 25, 2011, representing a 25 percent increase over the 12-month period ending April 2010